Key Points
- Director Gilbert Kliman sold 5,000 shares of Glaukos stock on May 11 at an average price of $135, totaling $675,000. After the sale, he still owned 35,528 shares, a 12.34% reduction in his stake.
- Glaukos reported better-than-expected quarterly results, posting EPS of -$0.18 versus the -$0.30 consensus and revenue of $150.57 million, up 41.2% year over year.
- Wall Street remains mostly positive on GKOS, with a consensus rating of “Moderate Buy” and an average price target of $144.42 after several firms raised targets or reiterated bullish ratings.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Gilbert Kliman sold 5,000 shares of the company's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $135.00, for a total value of $675,000.00. Following the completion of the sale, the director owned 35,528 shares in the company, valued at $4,796,280. This trade represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Glaukos Stock Performance
Shares of NYSE:GKOS opened at $137.19 on Thursday. The business's fifty day moving average price is $116.05 and its two-hundred day moving average price is $110.69. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $146.75. The stock has a market capitalization of $8.06 billion, a price-to-earnings ratio of -41.83 and a beta of 0.94. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million for the quarter, compared to analysts' expectations of $137.00 million. During the same period in the prior year, the business posted ($0.22) earnings per share. The business's revenue was up 41.2% compared to the same quarter last year. As a group, analysts predict that Glaukos Corporation will post -0.57 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
GKOS has been the topic of a number of analyst reports. Needham & Company LLC upped their price target on Glaukos from $127.00 to $136.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. Wall Street Zen upgraded Glaukos from a "hold" rating to a "buy" rating in a research report on Saturday, May 2nd. Piper Sandler reiterated an "overweight" rating and issued a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. BTIG Research upped their price target on Glaukos from $131.00 to $141.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. Finally, Citigroup increased their target price on Glaukos from $135.00 to $140.00 and gave the stock a "buy" rating in a report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and an average target price of $144.42.
Read Our Latest Analysis on GKOS
Institutional Trading of Glaukos
Several large investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 9.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock worth $158,000 after purchasing an additional 122 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 132 shares during the last quarter. CWM LLC grew its holdings in shares of Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock worth $80,000 after purchasing an additional 143 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Glaukos by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock worth $947,000 after purchasing an additional 144 shares during the last quarter. Finally, Evergreen Capital Management LLC grew its holdings in shares of Glaukos by 4.3% during the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 145 shares during the last quarter. Institutional investors own 99.04% of the company's stock.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
